NCT02823834进行中（未招募）不适用
Post Market Clinical Follow-up Study Protocol for PROFEMUR® Gladiator Plasma Femoral Stems and PROCOTYL® L Beaded Acetabular Components
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 121
- 试验地点
- 1
- 主要终点
- Component Survivorship
研究概览
简要总结
MicroPort Orthopedics (MPO) is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) components marketed in the European Union (EU). These types of studies are required by regulatory authorities for all THA devices that do not have medium to long-term clinical evidence available at the time of gaining approval to market in the EU. This study has been designed in accordance with the medial device directives (MEDDEV) 2.12/2 rev 2.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Has undergone primary THA for any of the following:
- •Non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, ankylosis, protrusio acetabuli, or painful hip dysplasia;
- •Inflammatory degenerative joint disease such as rheumatoid arthritis; or
- •Correction of functional deformity
- •Subject is implanted with the specified combination of components
- •Subject is willing and able to complete required study visits or assessments
- •Previously implanted bilateral subjects can have both THAs enrolled in the study provided:
- •the specified combination of components were implanted in both
- •all other aspects of the Inclusion/Exclusion Criteria are satisfied
- •enrollment does not exceed the subject count specified in the Clinical Trial Agreement
- •the subject agrees to a second Informed Consent document specific to the second THA.
排除标准
- •Subjects implanted with a metal-on-metal articulation
- •Subjects implanted with non-MPO or non-Wright Medical Technology components (femoral heads, acetabular shells, acetabular liners) at the time of their primary THA in the enrolled THA
- •Subjects skeletally immature (less than 21 years of age) at time of primary THA surgery
- •Subjects currently enrolled in another clinical study which could affect the endpoints of this protocol
- •Subjects unwilling to sign the Informed Consent document
- •Subjects with substance abuse issues
- •Subjects who are incarcerated or having pending incarceration
结局指标
主要结局
Component Survivorship
时间窗: 10 years post-operative
The primary objective of this study is to estimate survivorship analysis of all components at specified intervals out to 10 years follow-up.
次要结局
- Patient functional outcomes (hip specific)(2-5 years, 5-7 years and 10 years postoperatively beginning with first available visit)
- Patient functional outcomes (quality of life)(2-5 years, 5-7 years and 10 years postoperatively beginning with first available visit)
研究者
研究点 (1)
Loading locations...
相似试验
终止
不适用
Post Market Clinical Follow-up Study Protocol for PROFEMUR® Xm Femoral StemsJoint DiseaseNCT02309593MicroPort Orthopedics Inc.52
终止
不适用
Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Gladiator Cemented Femoral StemsJoint DiseaseNCT02397746MicroPort Orthopedics Inc.75
进行中（未招募）
不适用
Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Preserve Femoral StemJoint DiseaseNCT03865667MicroPort Orthopedics Inc.63
Enrolling By Invitation
不适用
Post Market Clinical Follow-Up Study Protocol for PROCOTYL® C Acetabular ComponentsJoint DiseaseNCT03576573MicroPort Orthopedics Inc.143
终止
不适用
Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Gladiator HA Coated Modular Femoral StemsJoint DiseaseNCT02314611MicroPort Orthopedics Inc.154